Lupus
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Md Yuzaiful Md Yusof Yuz6Yusof
11 months 2 weeks ago
Missed the Live #EULAR2024 #lupus #SLE Topic Recap session yesterday? You can catch up using the link below.
https://t.co/NYJgNb5ME0
@RheumNow @andreafava https://t.co/eeoSux6Csl
Dr. John Cush RheumNow
11 months 3 weeks ago
Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
https://t.co/y9QPieV0py https://t.co/GzwntEJLve
Dr. John Cush RheumNow
11 months 3 weeks ago
3 Big Lupus Themes from EULAR 2024
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria, including abstracts POS0732 and OP0255.
https://t.co/XD1EJW2nNE https://t.co/jALVfebb8t
Dr. John Cush RheumNow
11 months 3 weeks ago
Belimumab’s Sustained Impact in Lupus
SLE a chronic autoimmune multi-system inflammatory condition, can present with various, sometimes severe, clinical manifestations, leading to high levels of morbidity including impact on quality of life.
https://t.co/4Gf5SJN5FG https://t.co/LxCjLQkaYQ
Glucocorticoids (GC) have been the mainstay of treatment in SLE for nearly three quarters of a century. GC induce a range of anti-inflammatory effects, quickly relieve some symptoms and lower mortality in some life-threatening flares. However, they also have multiple side effects that limit the duration of treatment, as well as the dose used. Accordingly, the 2023 EULAR recommendations for SLE set a target dose of ≤5mg/day. Is low dose GC an
Janet Pope Janetbirdope
11 months 3 weeks ago
Summary of #EULAR2024 #ClinicalPearls
JAKi have expanding disease data
✅ #GCA w #UPA
✅ Awaiting data in #SLE w #UPA & #Deucravacitinib
✅Use in #JIA
✅No new safety signals
@rheumnow
@eular_org
Dr. John Cush RheumNow
11 months 3 weeks ago
Does B Cell Depletion Matter?
Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria.
https://t.co/IjxGWWjoGD https://t.co/GwLjB4Z7ub
Md Yuzaiful Md Yusof Yuz6Yusof
11 months 3 weeks ago
#EULAR2024 POS1325 Childhood onset #lupus is often more severe with high mortality rate. Similar to findings in adults, 2 cSLE patients with refractory disease including failure to CyC, RTX & PLEX responded to CD19 CAR T cells with similar short term safety profile @RheumNow https://t.co/YD2arjxcso
Md Yuzaiful Md Yusof Yuz6Yusof
11 months 3 weeks ago
#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7
Md Yuzaiful Md Yusof Yuz6Yusof
11 months 3 weeks ago
#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr
Nouf Al hemmadi NoufAhmedAlham2
11 months 3 weeks ago
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Poster Hall